News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
New and experimental hepatitis C treatment
Regulators Await Gilead's Hep C Candidate

Gilead Sciences’ (GILD) sofosbuvir has passed all its preliminary examinations, and now is looking like a good bet for regulatory submissions in the coming months.

Published
22 February 2013
From
Seeking Alpha
EASL publishes first comprehensive literature review on the burden of liver disease in Europe

Key findings in the report suggest that alcohol consumption, viral hepatitis B and C and metabolic syndromes related to overweight and obesity are the leading causes of cirrhosis and primary liver cancer in Europe.

Published
22 February 2013
From
Eurekalert Inf Dis
New and experimental hepatitis C treatment
Study may help design better DAA drug cocktails to treat HCV

The new study documents HCV kinetic modeling during treatment both in patients and in cell culture that provides insight into the modes of action of daclatasvir. In addition, the study suggests a more accurate estimate of HCV clearance from circulation.

Published
20 February 2013
From
News Medical
Hepatitis C transmission and prevention
Republic of Georgia plagued by hepatitis C

Official statistics place the number of those infected with the illness at 200,000, which is approximately 6.7 percent of Georgia’s population.

Published
20 February 2013
From
Vaccine News Daily
Hepatitis C transmission and prevention
Scotland: Project launched to tackle spread of Hepatitis C

It is hoped that by giving early treatment to small numbers of people who inject drugs and are infected with hepatitis C, it will prevent the need to treat larger numbers later, reducing the risk of addicts suffering from liver cirrhosis and cancer which can develop over time if hepatitis C remains untreated.

Published
20 February 2013
From
The Scotsman
New and experimental hepatitis C treatment
Gilead's Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study

Initial Regulatory Filings Planned for Q2 2013. Gilead Sciences (Nasdaq:GILD) today announced topline results from the Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin (RBV) in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus (HCV) infection who failed prior treatment.

Published
19 February 2013
From
Gilead press release
Hepatitis C
Triple trouble: infection with hepatitis B increases risk of death for people with HIV and hepatitis C co-infection

Infection with hepatitis B virus (HBV) is associated with a poorer prognosis for people living with HIV who are co-infected with hepatitis C virus (HCV), Spanish investigators

Published
19 February 2013
By
Michael Carter
Hepatitis C treatment
A 'Killer' of a Reason to Treat Hepatitis C: Video

Dr. David Johnson, Professor of Medicine and Chief of Gastroenterology at Eastern Virginia Medical School in Norfolk, Virginia, discusses the treatment of hepatitis C in patients with cirrhosis.

Published
18 February 2013
From
Medscape (requires registration)
Hepatitis C treatment
Victrelis (boceprevir) label updates

On February 13, 2013, FDA approved changes to the Victrelis (boceprevir) label to expand the indication to include the treatment of prior null responders.

Published
18 February 2013
From
FDA
Hepatitis C treatment side-effects
Drug interaction warning for hepatitis C: serious side effects when using telaprevir and bosentan

A medical team in Paris, France, has reported an unexpected and disturbing drug interaction between a drug used to treat pulmonary arterial hypertension—bosentan (Tracleer)—and the HCV drug telaprevir. The interaction led to serious side effects.

Published
15 February 2013
From
CATIE
← Prev1...23456...59Next →

Filter by country